We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I recall the IPO of Shire Pharmaceuticals. Look what happened to them!
Am I holding my shares for the longer term. Absolutely. For me, the bigger picture is what part does NCYT play in the UKs new diagnostic capability? Fascinating ...
gla.
Codey good point. However, other countries selecting the NCYT product may wish to see that NCYT have captured/major player in their home market. It gives the other countries confidence. Moreover, the UK is appearing to be very stringent in their assessments of the many tests available. This is a filter at the UKs cost, perhaps something that other countries value either on the basis of cost or given that they are unable to perform such verification. The UK had now down selected 3 PCR test products abd is still evaluating the antibody test.
I use the phrase appear as a chink in my argument is the Chinese test that we procured. Article in Guardian (3/4/30) indicates a mere 7.5 million tests. Are these the tests with 25% conformance with positive test cases? This figure is similar to the 30% figure Spain announced. Bottom line, a lot of money. Now once bitten twice shy PHE are being more thorough. I digress ...
Rule 1, never give up on a sale. Selling to 80 countries is great.
Rule2, capture/be a major player in your home market.
The science behind the NCYT test is unassailable and compelling and that is why it remains at the top of the assay table.
The UK's Primerdesign (PCR) test provides an 'unmatched [diagnostic] tool' which has '100% homology' with Covid-19 and is one of the most accurate available. As of 27th March 2020 PrimerDesign can comfirm 100% homology with the 1743 full length good quality SARS-CoV-2 sequences published on the GISAID EpiCoV database. Noone else is making this bold claim.
Additionally the FDA are now reviewing the FDA EUA's they granted. No one wants to us a bad test
Professor Whitty (uk) warned that the 'one thing worse than no test is a bad test". For me, all this puts NCYT in a strong position as a major player. Are we the cornerstone of the UKs new diagnostic capability. If we are then a little minnow from Southampton is about to join the premier league. Silver, hopefully we move from the AIM manipulative market!
gla
The 3/4 failure was re antibody tests as mentioned on Newsnight
Atisha, he didn't say 'the first 3 suppliers test had failed'. He said ONE supplier had 3 out of four tests fail, so only had a 25% success rate.That is how I thought it was anyway.
This has been played/held back for many weeks. The real value hasn't arrived yet. As Han**** said tonight; "The first 3 suppliers tests have failed." As far as we all know this is the number 1 test, so we stand in a strong position with the NHS let alone the rest of the world.
The world is desperate at this point of time and any quality test/antibody kit will be more than welcome.
Could you please explain to me share consolidation or point me in the direction of some good reading on the subject?
Haha yeh. Some of the very earliest buyers could end up 5000% up here.
Ok, @gggg21 - but it looks great! :-)) Still has a huge upside!
Not quite as quickly as NCYT will rise mind!
Due to share consolidation haha so not actually
Wow, so many posts on this board amazing! I managed to add another £10K today, just not quite at the bottom. Still growing with confidence. This is a great place to be. Up to £45k now added.
Very exciting day in the energy storage world. Don’t think you see this often but Redt a little Vanadium Redox Flow Battery manufacturers up over 5000% - yes have a look!
No ramping or hardly any posts....just supply energy storage to the Oxford Energy Hub and has the potential for 40 other large projects. Shush, keep it quiet don’t tell anyone;-)
I am looking forward to our next RNS here, we might not be up 5000% but I am sure it will be significant. The assay is very strong. Very few companies have such a strong product and the orders are clearly off the scale. Just a shame this is listed on AIM. Should be moved to the FTSE and get away from those manipulating market markers...
Have a good night all and keep safe!
Cheers RK